Purchase this article with an account.
L.-H. Chuang, W.-C. Wu, C.-C. Lai, L. Yeung, N.-K. Wang, Y.-P. Chen; Serum Concentration of Bevacizumab After Intravitreal Injection in Experimental Branch Retinal Vein Occlusion. Invest. Ophthalmol. Vis. Sci. 2008;49(13):4576.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the serum concentration of Bevacizumab after intravitreal injection in experimental branch retinal vein occlusion of albino rats.
A total of 32 albino rats were included. Sixteen rats were served as control and branch retinal vein occlusion (BRVO) was created in one eye of the other 16 rats. The BRVO was generated by photothrombosis. Briefly, laser photocoagulation was applied to 2 to 3 major retinal veins after intravenous injection of rose Bengal till venous occlusion. Five µL Bevacizumab was then injected intravitreally to the BRVO eyes 3 days after thrombosis. One eye of the control group was injected as a similar fashion. The concentration of Bevacizumab in serum was monitor on 6 hour, 1 days, 3 days, 7 days, 14 days and 28 days after injection.
The serum concentration of Bevacizumab reached its peak on day 1 either in BRVO or control eyes. Then, the concentration declined slowly till 28 days after injection. Although the average serum concentration of Bevacizumab was higher in BRVO rats than the control on every time points, however, it is not significant.
The serum concentration of Bevacizumab reached its peak on day 1 either in BRVO or control eyes. During the survey, the serum concentration of Bevacizumab was higher in BRVO rats than the control.
This PDF is available to Subscribers Only